Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Arzanol is a prenylated phloroglucinol-α-pyrone heterodimer natural product isolated from the Mediterranean plant *Helichrysum italicum*. It functions as a multi-target small molecule with potent anti-inflammatory, antioxidant, and antimicrobial properties. Its primary mechanism involves the dual inhibition of microsomal prostaglandin E2 synthase-1 (mPGES-1) and 5-lipoxygenase (5-LOX), effectively blocking the biosynthesis of pro-inflammatory eicosanoids. Arzanol also modulates the NF-κB signaling pathway, activates SIRT1, and inhibits human dihydroorotate dehydrogenase (hDHODH) and brain glycogen phosphorylase. Research has explored its potential in treating inflammatory conditions, various cancers (notably bladder cancer), metabolic disorders, and viral infections including SARS-CoV-2. Currently in the preclinical stage, its development faces challenges such as high serum protein binding which impacts its pharmacokinetic profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on arzanol.